

Regulation Tracking Log

Regulation Number and Topic	Workshop Propose To Bd	30 Days To LCB W/Letter	LCB R0 Number Issued	LCB Return Date	30 Days Post Public Hearing	Public Hearing Meeting Date	To LCB Final W/ Cov./Info	Secretary of State File Date
453.450 Schedule IV - Tramadol	07/24/14	08/13/14	R133-14	08/21/14	09/16/14	10/16/14	03/03/15	06/26/15
639.67** Compounding of Nasal Sprays	09/03/14 10/16/14	10/22/14	R140-14					
453.530 Schedule III - Hydrocodone	09/03/14	09/09/14	R137-14	10/22/14	10/23/14	12/03/14	12/12/14	12/22/14
453.520 Schedule II - Hydrocodone	09/03/14	09/09/14	R138-14	10/22/14	10/23/14	12/03/14	R138-14 included in R137-14	12/22/14
453.510 Schedule I – Adding certain controlled substances.	12/03/14	12/12/14	R142-14	07/31/15	08/26/15	10/15/15	10/28/15	12/21/15
639.050 Storage & Destruction of Certain Drugs	01/22/15	02/17/15	R002-15	07/31/15	08/26/15	10/15/15	10/28/15	12/21/15
639.6282 3PLs 639.6305 3PLs	01/22/15	02/17/15	R001-15	08/03/15	08/26/15	10/15/15 12/02/15 01/13/16 04/14/16	07/29/16	
639.NEW Outsourcing Facilities	01/22/15	02/17/15	R003-15	08/18/15	08/26/15	10/15/15	10/28/15	12/21/15
453.510 Schedule I – Adding certain controlled substances.	04/16/15	04/29/15	Added to R142-14	07/31/15	08/26/15	10/15/15	10/28/15	12/21/15
453.540 Schedule IV - Suvorexant	04/16/15	04/29/15	R004-15	05/05/15	05/06/15	06/10/15	07/14/15	08/10/15
639.926 Transmission of CS Info	06/10/15	07/02/15	R047-15	09/17/15	10/28/15	12/02/15 01/13/16	01/27/16	04/04/16
453.510 Schedule I Cannabis, Cannabidiol & Acetyl Fentanyl	09/02/15	09/08/15	R080-15	09/28/15				
453.540 Lorcazerin – Schedule IV	09/02/15	09/08/15	R079-15	09/17/15	10/28/15	12/02/15 01/13/16	01/27/16	04/04/16

Regulation Tracking Log

Regulation Number and Topic	Workshop Propose To Bd	30 Days To LCB W/Letter	LCB R0 Number Issued	LCB Return Date	30 Days Post Public Hearing	Public Hearing Meeting Date	To LCB Final W/ Cov./Info	Secretary of State File Date
453.NEW Naloxone	09/02/15 10/15/15	10/22/15	R121-15	04/29/16	06/15/16	07/20/16	08/05/16	09/09/16
639.955 Penalty for failing to transmit information required by NAC 639.926	03/02/16	03/11/16	R036-16	04/08/16	04/27/16	06/01/16	06/16/16	06/28/16
639.921 Sharing information between systems.	03/02/16	03/11/16	R035-16	04/08/16	06/15/16	07/20/16	Denied 07/21/16	
453.NEW Naloxone	01/13/16	04/07/16	R058-16	05/04/16	06/15/16	07/20/16	08/05/16	09/09/16
639.7102 Use of computer system for issuance and transmission of prescription	07/21/16 09/08/16 10/13/16	10/25/16	R154-16					
639.7105 Electronic transmission of prescription								
NAC 453.510 Schedule I add MAB-CHMINACA, AB-FUBINACA and ADB-PINACA	09/08/16	09/20/16	R151-16					
453.540 Schedule IV add Eluxadoline	09/08/16	09/20/16	R150-16					
453.550 Schedule V add Brivaracetam	09/08/16	09/20/16	R149-16					
453.NEW Naloxone recordkeeping	10/13/16	10/25/16						
453.460 Partial Filing of Prescriptions	03/01/17							

TEMPORARY LICENSES
(Issued since last board meeting)

CVS/pharmacy

Angel Qin



NABPF
National Association of Boards
of Pharmacy Foundation
www.nabp.pharmacy

1600 Feehanville Drive
Mount Prospect, IL 60056
T) 847/391-4406
F) 847/375-1114

January 31, 2017

Via E-mail

Jason Penrod
Nevada State Board of Pharmacy

Dear Jason Penrod:

Congratulations! Your application to the National Association of Boards of Pharmacy Foundation® (NABPF™) Annual Meeting Travel Grant Program has been accepted. However, please note that this approval is contingent upon your Board's presence at the Annual Meeting during all business sessions. Your Board of Pharmacy must have their designated voting delegate in attendance at all three business sessions in order for you to receive reimbursement through the NABPF grant.

The program will reimburse your travel expenses up to \$1,500. Annual Meeting registration fees are **not** covered by the travel grant; however, hotel, transportation, and meals are covered. I have enclosed a copy of the NABPF travel reimbursement policy along with a travel grant expense form. We encourage you to register for the meeting online as soon as possible, via the link: <https://nabp.pharmacy/meetings-categories/annual-meetings/> (click on "Register for and Learn More About the 2017 Annual Meeting"). The meeting will take place May 20-23, 2017, in Orlando, FL.

NABP has put together a terrific blend of educational programs and special events specifically designed to help you, your board members, and board staff meet this year's challenges. Returning to the program this year are many of the featured programming and special events that have been highly rated by attendees at previous meetings. The Annual Meeting and District Meeting Orientation, the Informal Member/Candidate Discussion, Hospitality Brunch, Educational Table Top Display, and Annual Awards Dinner will all be back. Please join NABP as we kick off the 113th Annual Meeting with the President's Welcome Reception at the Hyatt Regency Orlando in Orlando, FL.

If you have any questions, please contact me via phone at 847/391-4400 or email me at ExecOffice@nabp.pharmacy. I look forward to seeing you in Orlando!

Sincerely,

NATIONAL ASSOCIATION OF
BOARDS OF PHARMACY FOUNDATION

A handwritten signature in cursive script, appearing to read "Carmen A. Catizone".

Carmen A. Catizone, MS, RPh, DPh
Executive Director/Secretary

Attachments: Travel Grant Expense Form
 Travel Grant Reimbursement Policy

CC/lj


Researchers Develop Safer Opioid Painkiller From Scratch

Imagine a painkiller as effective as morphine but without its sometimes deadly side effects.

That's the potential of a new drug co-created by Brian Shoichet, PhD '91, a professor of pharmaceutical chemistry at UC San Francisco; Bryan Roth, MD, PhD, at the University of North Carolina at Chapel Hill; Peter Gmeiner, PhD, at Friedrich-Alexander University in Germany; and 2012 Nobel Laureate Brian Kobilka, MD, at Stanford University. Notably, the new drug does not interfere with breathing – the main cause of overdose deaths from prescription painkillers, as well as from street narcotics like heroin; it also does not cause constipation, another common opioid side effect. In addition, the new drug appears to sidestep the brain's dopamine-driven addiction circuitry, as it does not cause drug-seeking behavior in mice.

Just as important as the drug itself is the radical new method the team used to create it. Drug discovery typically begins by tweaking the structure of a successful drug like morphine, to try to get rid of its side effects while maintaining its primary function. But Shoichet and his colleagues sought to create an entirely new chemical compound that would block pain without causing opioids' undesirable side effects.

To do this, they started from scratch – with computational techniques that let them explore more than four trillion different chemical interactions – and then used the newly deciphered atomic structure of the brain's "morphine receptor" to custom engineer a novel drug candidate. This computational approach, called molecular docking, was pioneered in the 1980s at UCSF's School



The new, safer opioid drug candidate, PZM21, is shown docked on the brain's morphine receptor, the mu-opioid receptor.

of Pharmacy by Shoichet's mentor, Professor Emeritus Tack Kuntz, PhD.

More work is needed to establish that the newly formulated compound is truly non-addictive and to confirm that it is safe and effective in humans. But if the initial findings are borne out, they could transform the fight against the rising epidemic of addiction to prescription painkillers.



Nevada State Board of Pharmacy

431 W. PLUMB LANE • RENO, NEVADA 89509
(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444
E-mail: pharmacy@pharmacy.nv.gov • Website: bop.nv.gov

NEVADA STATE BOARD OF PHARMACY

ACTIVITIES REPORT

JANUARY 11, 2017 BOARD MEETING HELD IN LAS VEGAS, NEVADA

This report is prepared and presented to keep interested legislators and others abreast of the activities of the Nevada State Board of Pharmacy. Following is a summary of the January, 2017 Board meeting.

Licensing Activity:

- 6 licenses were granted for Out-of-State MDEG (Medical Devices, Equipment and Gases) companies.
- 16 licenses were granted for Out-of-State pharmacies, pending receipt of a favorable inspection for all compounding pharmacies.
- 15 licenses were granted for Out-of-State wholesalers.
- 5 licenses were granted for Nevada pharmacies & 1 application withdrawn.
- 2 licenses were approved for Nevada MDEG's and 1 tabled for more information.
- Pharmacist JC, who was revoked a year ago for diversion, was granted a conditional license and put on probation pending the gathering of further information.

Disciplinary Actions:

- Pharmacist RA was fined \$750; reprimanded and ordered 3 additional hours of CE for filling a mirtazepam (antidepressant) prescription with temazepam (sleeper) and failing to adequately counsel the patient. Pharmacy CV was fined \$495.
- Pharmacy MD was cited and fined \$3K for operating unlicensed and the managing pharmacist's case continued at her request.
- Pharmacy technician JC was admonished, fined and ordered CE for working unlicensed; pharmacists MF and TF were ordered the same for allowing JC to work unlicensed, and pharmacy CH was fined and ordered to develop policies and procedures to prevent such activity from happening again.
- Pharmacy WC was fined \$1K plus a \$2500 admin fee for numerous sterile compounding violations and agreed to cease sterile compounding.

Other Activity:

- The usual Board business reports were given, including recent and future speaking engagements; reports on national meetings; and collaboration with other state agencies.